21 May 2013
Keywords: wt-kras, erbitux, efficacy, biomarker, german, drugmaker, merck
Article | 04 February 2008
German drugmaker Merck KGaA says that data from three studies of the anticancer agent Erbitux (cetuximab) indicate that it is ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
4 February 2008
20 May 2013
© 2013 thepharmaletter.com